Jingjing Zhang

Dr. Jingjing Zhang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
RBRichard P. Baum
Richard P. Baum
JZJingjing Zhang
Jingjing Zhang
CSChristiane Schuchardt
Christiane Schuchardt
DMDirk Mueller
Dirk Mueller
HMHelmut Maecke
Helmut Maecke
The objective of this study was to assess the safety, dosimetry, and efficacy of the 177Lu-labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2 (177Lu-DOTA-LM3) in patients with metastatic neuroendocrine neoplasms (NENs). Methods: Fifty-one patients (age 27–76, mean 51.6±13.9 years) with metastatic NENs underwent peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-LM3 between August 2017 and December 2019. The median administered activity per cycle was 6.1±0.88 GBq (range 2.8–7.4 GBq). 68Ga-NODAGA-LM3 PET/CT was used for patient selection and follow-up after 177Lu-DOTA-LM3 PRRT. Morphologic and molecular responses were evaluated in accordance with RECIST 1.1 and European Organization for Research and Treatment of Cancer (EORTC) criteria. Treatment-related adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Dosimetry was performed in 11 patients and compared with the SSTR agonist 177Lu-DOTATOC in 247 patients undergoing PRRT on the same dosimetry protocol. Results: Higher uptake and a longer effective half-life of 177Lu-DOTA-LM3 was found for whole-body as well as kidneys, spleen, and metastases, resulting in higher mean absorbed organ and tumor doses as compared to the agonist 177Lu-DOTA-TOC. All patients tolerated therapy without any serious acute adverse effects. Mild nausea without vomiting was observed in 5 (9.8%) patients; no other symptoms were reported. The most severe delayed adverse event was CTC-3 thrombocytopenia in 3 (5.9%) patients. Neither CTC-4 thrombocytopenia nor CTC-3-4 anemia or leukopenia was observed after treatment. No significant decline in renal function was observed, nor was hepatotoxicity. According to RECIST 1.1, disease control could be reached in 40 patients (disease control rate, 85.1%) of 47 patients monitored after 177Lu-DOTA-LM3 PRRT, with a partial response in 17 (36.2%) and stable disease in 23 (48.9%), whereas 7 (14.9%) patients had progressive disease, and by EORTC criteria, complete remission in 2 (4.3%), partial remission in 21 (44.7%), stable disease in 18 (38.3%), and progressive disease in 6 (12.8%) patients. Conclusion: “Antagonist PRRT” with 177Lu-DOTA-LM3 could be administered without severe adverse effects and was well tolerated by the majority of patients, with thrombocytopenia occurring only in a few patients. No other severe adverse effects were observed, particularly no nephrotoxicity. The SSTR antagonist 177Lu-DOTA-LM3 appears to be very promising for PRRT, provides favorable biodistribution and higher tumor radiation doses than SSTR agonists, and was very effective in treating advanced metastatic NENs, especially in patients with low or no SSTR agonist binding, even achieving complete remission in some patients.

16 August 2018 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
JZJingjing Zhang
Jingjing Zhang
HKHarshad R. Kulkarni
Harshad R. Kulkarni
ASAviral Singh
Aviral Singh
KNKarin Niepsch
Karin Niepsch
DMDirk Müller
Dirk Müller
RBRichard P. Baum
Richard P. Baum
To date, limited data are available concerning peptide receptor radionuclide therapy (PRRT) of grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferation index of >20%. The purpose of this study was to analyze the long-term outcome, efficacy and safety of PRRT in patients with SSTR-expressing G3 NEN. Methods: A total of 69 patients (M=41 males; age 28-81 years) received PRRT with lutetium-177 (177Lu) and/or yttium-90 (90Y) labeled somatostatin analogs (DOTATATE or DOTATOC). Twenty-two patients had radiosensitising chemotherapy. Kaplan–Meier analysis was performed to calculate progression-free survival (PFS) and overall survival (OS), defined from start of PRRT, including a subgroup analysis for patients with a Ki-67 of ≤55% and >55%. Treatment response was evaluated according to RECIST 1.1 as well as by molecular imaging criteria (EORTC). Short and long-term toxicity was documented (CTCAE v.5.0) using a structured database (comprising over 250 items per patient) and retrospectively analyzed. Results: Forty-six patients had pancreatic, 11 CUP, 6 midgut, 3 gastric, and 3 rectal NEN. Median follow-up was 94.3 months. The median PFS was 9.6 months and median OS was 19.9 months. For G3 NEN with a Ki-67 ≤55% (n = 53), the median PFS was 11 months and median OS 22 months. Patients with a Ki-67 >55% (n = 11), had a median PFS of 4 months and a median OS of 7 months. For those patients with positive SSTR imaging, but no FDG uptake, the median PFS was 24 months and median OS was 42 months. A significant difference was found for both, PFS and OS, with a median PFS of 16 vs 5 months and a median OS of 27 vs 9 months for a SUVmax >15.0 and a SUVmax ≤15.0 on SSTR-PET, respectively. In the group with FDG scored as 3-4, the median PFS was 7.1 months and the median OS 17.2 months. For FDG scored as 0-2, the median PFS was 24.3 months and the median OS 41.6 months. PRRT was well-tolerated by all patients; no grade 3 or grade 4 hematotoxicity occurred and no clinically significant decline in renal function was observed. There was no hepatotoxicity. Conclusion: PRRT was tolerated well without significant adverse effects and is efficacious in G3 NEN with promising clinical outcome, especially in patients with a Ki-67 index of ≤55% and even in patients who have failed chemotherapy. Baseline FDG along with SSTR molecular imaging is useful to stratify those G3-NEN patients with high uptake on SSTR PET/CT and no or minor FDG-avidity, a mismatch pattern which is associated with a better long term prognosis.

9 November 2017 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
JZJingjing Zhang
Jingjing Zhang
GNGang Niu
Gang Niu
XFXingrong Fan
Xingrong Fan
LLLixin Lang
Lixin Lang
GHGuozhu Hou
Guozhu Hou
XCXiaoyuan Chen
Xiaoyuan Chen
This study was designed to study the safety, biodistribution, radiation dosimetry of a gastrin-releasing peptide receptor (GRPR) antagonist positron emission tomography (PET) tracer 68Ga-RM26, to assess its clinical diagnostic value in prostate cancer patients, and to perform a direct comparison between GRPR antagonist 68Ga-RM26 and agonist 68Ga-BBN. Methods: Five healthy volunteers were enrolled to validate the safety of 68Ga-RM26 and calculate dosimetry. A total of 28 patients with prostate cancer (17 newly diagnosed and 11 post therapy) were recruited with written informed consent. All the cancer patients underwent PET/CT scans at 15-30 min after intravenous injection of 1.85 MBq (0.05 mCi) per kilogram body weight of 68Ga-RM26. Among them, 22 patients (11 newly diagnosed and 11 post therapy) accepted 68Ga-BBN PET/CT for comparison within 1 week. 99mTc-MDP bone scans were performed within 2 weeks for comparison. GRPR immunohistochemical staining of tumor samples was performed. Results: The administration of 68Ga-M26 was well tolerated by all subjects with no adverse symptoms being noticed or reported during the whole procedure and 2 weeks follow up. The total effective dose equivalent (EDE) and effective dose (ED) were 0.0912 ± 0.0140 and 0.0657 ± 0.0124 mSv/MBq, respectively. In the 17 patients with newly diagnosed prostate cancer, 68Ga-RM26 PET/CT showed positive prostate-confined findings in 15 tumors with SUVmax of 6.49 ± 2.37. In the 11 patients underwent prostatectomy or brachytherapy with/without androgen deprivation therapy (ADT), 68Ga-RM26 PET/CT detected 8 metastatic lymph nodes in three patients with SUVmax of 4.28 ± 1.25, and 21 bone lesions in 8 patients with SUVmax of 3.90 ± 3.07. Compared with 68Ga-RM26 PET/CT, GRPR agonist 68Ga-BBN PET/CT detected less primary lesions and lymph node metastases as well as lower tracer accumulation. There was a significant positive correlation between SUV derived from 68Ga-RM26 PET and the expression level of GRPR (P < 0.001). Conclusion: This study indicates the safety and significant efficiency of GRPR antagonist 68Ga-RM26. 68Ga-RM26 PET/CT would have remarkable value in detecting both primary prostate cancer and metastasis. 68Ga-RM26 is also expected to be better than GRPR agonist as an imaging marker to evaluate GRPR expression in prostate cancer.

13 March 2020 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JZJingjing Zhang
Jingjing Zhang
QLQingxing Liu
Qingxing Liu
ASAviral Singh
Aviral Singh
CSChristiane Schuchardt
Christiane Schuchardt
HKHarshad Rajaram Kulkarni
Harshad Rajaram Kulkarni
RBRichard P. Baum
Richard P. Baum
The objective of this retrospective study was to determine the role of 18F-FDG PET/CT in a large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were treated with peptide receptor radionuclide therapy (PRRT) with a long-term follow-up. Methods: The 495 patients were treated with 177Lu- and/or 90Y- DOTATOC/DOTATATE PRRT between 2/2002 and 7/2018. All subjects received both 68Ga-DOTATOC/TATE/NOC and 18F-FDG PET/CT prior to treatment and were followed 3-189 months. Kaplan-Meier analysis, log-rank test (Mantel-Cox), and Cox regression analysis were performed for overall survival (OS) and progression-free survival (PFS). Results: 199 patients (40.2%) presented with pancreatic NEN, 49 with CUP (cancer of unknown primary), 139 with midgut NEN, whereas the primary tumor was present in the rectum in 20, in the lung in 38, in the stomach in 8 and other locations in 42 patients. FDG-PET/CT was positive in 382 (77.2%) patients and 113 (22.8%) were FDG-negative before PRRT, while 100% were 68Ga-DOTATOC/TATE/NOC positive. For all patients, the median PFS and OS, defined from start of PRRT, were 19.6 mo and 58.7 mo, respectively. Positive FDG predicted shorter PFS (18.5 mo vs 24.1 mo; P = 0.0015) and OS (53.2 mo vs 83.1 mo; P < 0.001) than negative FDG. Amongst the pancreatic NEN, the median OS was 52.8 mo in FDG positive and 114.3 mo in FDG negative subjects (P = 0.0006). For all patients with positive 18F-FDG uptake, and a ratio of the highest SUVmax on 68Ga-SSTR PET to the most 18F-FDG-avid tumor lesions >2, the median OS was 53.0 mo, compared to 43.4 mo in those patients with a ratio 15.0 and ≤15.0 on 68Ga-SSTR PET/CT, respectively. Conclusion: The presence of positive lesions on 18F-FDG PET is an independent prognostic factor in patients with NEN treated with PRRT. Metabolic imaging with 18F-FDG PET/CT compliments the molecular imaging aspect of 68Ga-SSTR PET/CT for the prognosis of survival after PRRT. High SSTR expression combined with negative 18F-FDG PET/CT imaging is associated with the most favorable long-term prognosis.

8 March 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JZJingjing Zhang
Jingjing Zhang
HKHarshad R. Kulkarni
Harshad R. Kulkarni
ASAviral Singh
Aviral Singh
CSChristiane Schuchardt
Christiane Schuchardt
KNKarin Niepsch
Karin Niepsch
RBRichard P. Baum
Richard P. Baum
The aim of this study was to assess the safety, tolerability and effects on renal function as well as therapeutic efficacy of prostate-specific membrane antigen (PSMA) targeted radioligand therapy (PRLT) using lutetium-177 (177Lu) labeled PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) and a single functioning kidney before PRLT. Methods: Sixteen patients (age 53-78 y, mean age 64.7 ± 6.5 y) with a single functioning kidney received PRLT with 177Lu-PSMA-617 between March 2015 and October 2018. All parameters of renal function (serum creatinine, blood urea nitrogen and electrolytes) were prospectively documented in a structured database and analyzed prior to each PRLT cycle and in follow-up. Renal function was further quantified by measuring TER using 99mTc-MAG3 renal scintigraphy. Treatment-related adverse events (AEs) were graded according to the CTCAE v.5.0. Kaplan-Meier analysis was performed to obtain the progression-free survival and overall survival. Results: The median administered activity was 22.1 GBq (range 15.4-33.8 GBq). Calculated radiation-absorbed doses of kidney per cycle were 5.3 ± 2.1 Gy (0.81±0.32 Gy/GBq). Renal function was already impaired at baseline in 43.7% patients, including G1 renal impairment in 25.0% and G2 in 18.8%. G1 and G2 renal impairment, respectively, were present in 37.5% and 6.3% of the patients after the first PRLT cycle and in 31.3 % and 12.5% after the second cycle. No G3 or 4 nephrotoxicity was observed during or after treatment. There was no significant change in both tubular extraction rate (TER) and the ratio of to lower limit TER (TER/TERLoLi) after the last cycle of treatment (p>0.05). The median PFS was 8.1 months based on both EORTC and RECIST. The median overall survival has yet to be reached with a median follow-up time of 19.3 months (range 5.8-45.3 months). Conclusion: In patients with a single functioning kidney, 177Lu-PSMA-617 radioligand therapy is feasible, seems to be effective and is very well tolerated without any signs of acute or subacute nephrotoxicity during a mean follow up of nearly 2 years (and up to 45.3 mo). Further long-term follow-up of this special patient group is warranted.

6 July 2021 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
JZJingjing Zhang
Jingjing Zhang
HKHarshad R. Kulkarni
Harshad R. Kulkarni
RBRichard P. Baum
Richard P. Baum
Somatostatin receptor–targeted α-therapy using α-emitter 225Ac-labeled somatostatin analogs has been suggested as a treatment option in advanced metastatic neuroendocrine tumors (NETs) failing treatment with β-emitters, such as 177Lu or 90Y. Thymus NETs are rare and usually more aggressive than other neuroendocrine tumor entities. We present here a case with β-radiation refractory metastatic thymus NET, who demonstrated an excellent therapy response (molecular and morphological remission, as well as significantly improved clinical symptoms) after 225Ac-DOTATOC–targeted α-therapy, without any adverse effects during the treatment or in the follow-up period.